About Targeted Medical Pharma

Corporate History

Targeted Medical Pharma Inc., (OTCQB: TRGM) is a Los Angeles-based biotechnology company founded in 1999, that develops medical foods for the treatment of chronic disease including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also manufactures a line of proprietary dietary supplements to support health and wellness. Targeted Medical Pharma commenced trading of its securities in October of 2012, under the symbol "TRGM" on OTC Market Group's OTCQB market and the Over-the-Counter Bulletin Board (OTCBB). Targeted Medical Pharma manufactures ten proprietary medical foods and develops a proprietary line of dietary supplements. These medical foods and therapeutic systems are sold to physicians and pharmacies throughout the United States and abroad. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs.

Targeted Medical Pharma Inc. was originally founded in 1999 as Targeted Medical Foods. The company has distributed proprietary Medical Foods and dietary supplements to physicians, pharmacies and patients in the United States since 2001. The early development of the Company's products began in the cardiovascular testing laboratory. Certain patterns of autonomic nervous system derangement were observed on long-term electrocardiographic (EKG) recordings. These abnormal patterns corresponded to specific disease states and were associated with conditions known to have increased nutritional requirements specific to certain diseases. Over a period of five years, Company scientists assembled an extensive database of peer reviewed medical and scientific journal articles that confirmed that the common threads linking certain disease states were a variety of neurotransmitter deficiencies and imbalances. The challenge was then to identify the anatomical cause of neurotransmitter depletion and to develop interventions that would encourage the body to restore healthy neurotransmitter levels that would ameliorate the symptoms of disease.

In 1998, the Company scientists joined a group of investigators from the University of Texas, Southwestern Medical Center to attempt to determine the underlying causes of Gulf War Syndrome, a condition characterized by neurotransmitter depletion. After many years of testing and analysis, the results of this study revealed that lesions in key areas of the brain were associated with the disease process. This work was published in November 2004 in the American Journal of Medicine.

Sentra AM and Sentra PM were the first products developed to address the needs of patients suffering from the effects of chemical exposures. Using the benchmark of Heart Rate Variability analysis to measure autonomic nervous system response to therapeutic interventions, the five-step process that became Targeted Cellular Technology was developed.

On April 10, 2003 Physician Therapeutics entered into a Licensing Agreement for the Sales and Marketing Rights for six proprietary TCT medicinal nutrient products with J Network, Inc ("JNT"). The exclusive agreement was signed and provides for Physician Therapeutics, a subsidiary of Targeted Medical Pharma Inc., to manufacture and JNT to distribute on a mass distribution brands known as Lister V, Sentra AM, Sentra PM, AppTrim, and Nutra Smokeless, in Japan.

In 2008, 2009, 2010 and 2011, the Company completed multiple double-blind placebo-controlled trials of medical foods used to manage pain, sleep and cognitive disorders. These studies demonstrated the efficacy of medical foods administered as a standalone medication and as an adjunct therapy to a low dose drug to manage disease without harmful side effects.

Physician Therapeutics' proprietary line of Medical Foods, are exclusive to the current Medical Foods marketplace having the unique ability to produce pharmacological effects and treat symptoms of diseases.

Since 2008, the Company has published five clinical trials in peer reviewed journals and presented data at multiple conferences throughout the United States.

In 2013, the Company embarked on the development of many new products. The Company released initial data regarding its' proprietary red blood cell stimulating formula. This formula is an oral amino acid-based erythrocyte stimulating system (ESS) for the treatment of chronic anemia. The ESS system is designed to stimulate progenitor stem cells in the bone marrow. In late 2013, the Company announced positive results from an observational study on the dietary management of autistic spectrum disorders, and plans to launch a formal study in 2014.

In November of 2013, the Company launched Clearwayz, a dietary supplement designed to support healthy sinus, lung and immune function. In September and October of 2014, the company published new data for the treatment of both low back pain and Posttraumatic stress disorder (PTSD). In a head-to-head study, published in the American Journal of Therapeutics, comparing Theramine to ibuprofen, Theramine proved to be more effective at relieving back pain and inflammation than ibuprofen alone. In this double-blind multicenter study, Theramine was shown to reduce inflammation more effectively than ibuprofen as measured by CRP and IL-6. These results confirm a previous study comparing naproxen to Theramine in a similar patient population.

In a separate publication in The Journal of Central Nervous System Disease, the Company published new data relating to the treatment of PTSD in military veterans using the medical foods Sentra AM and Sentra PM. In this study, subjects taking Sentra AM and Sentra PM for 30 days reported a 27% reduction in the symptoms of PTSD and a 57% increase in their mental health rating.

History: Targeted Medical Pharma Development Timeline

1996 Laboratory Industry Services LLC is founded as a Nevada limited liability
1998 Investigations into Gulf War Syndrome yield promising data regarding neurotransmitter depletion and disease.
1998 Targeted Medical Foods was established. Sentra AM and Sentra PM were developed and groundwork for Targeted Cellular Technology began.
2002 Targeted Medical Foods becomes a Limited Liability Corporation as Targeted Medical Pharma Inc.
2003 Targeted Medical Foods is established as a subsidiary of the company and primary Medical Food distributor.
2003 Physician Therapeutics enters into licensing agreement for the sales and marketing rights for six products with J Network, in Japan.
2003 Physician Therapeutics enters into licensing agreement with Pliva Krakow Pharmaceutical Company for European distribution.
2004 American Journal of Medicine publishes data and findings from the Gulf War Syndrome study. New York Times editorializes findings.
2006 Physician Therapeutics introduces first Convenience Packs for sale and distribution.
2008 First double-blind placebo controlled studies completed for Medical Foods and generic drugs.
2009 Four Medical Food patents are issued by the United States Patent and Trademark Office and assigned to Targeted Medical Pharma Inc.
2009 Double-blind clinical study completed for Theramine and naproxen.
2009 One Medical Food Patent is issued by the United States Patent and Trademark Office and assigned to Targeted Medical Pharma Inc.
2010 Double-blind placebo controlled study completed for Theramine and Ibuprofen.
2012 Theramine and naproxen double-blind clinical study published in the American Journal of Therapeutics.
2012 Company commences public trading of securities on the OTCBB under the symbol TRGM.
2012 Sentra PM and trazodone double-blind clinical study published in the Journal of Central Nervous System Disease.
2012 Two decades of research into Gulf War Illness by company founders culminate with confirmation of disordered parasympathetic activity.
2013 Comprehensive pharmaceutical billing patent issued by the United States Patent and Trademark Office and assigned to Targeted Medical Pharma.
2013 Initial data on the company’s erythrocyte stimulating system (ESS) for the treatment of chronic anemia released.
2013 Reported results from an observational study of the dietary management of autistic spectrum disorders with medical foods.
2013 Launched AminoLabs, a division of the company that specializes in the development and commercialization of proprietary dietary supplements.
2013 Launched Clearwayz for sustained sinus and immune support, the first in a line of dietary supplements.
2014 Published in the American Journal of Therapeutics, a second double-blind clinical study examining the effects of Theramine on chronic back pain and inflammation.
2014 Published in The Journal of Central Nervous System Disease, an open label, pilot study examining the effects of Sentra AM and Sentra PM on PTSD.